| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 93 | 2021 | 2502 | 13.380 |
Why?
|
| Lung Diseases, Interstitial | 29 | 2021 | 191 | 10.240 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 20 | 2021 | 136 | 7.970 |
Why?
|
| Lung | 32 | 2021 | 1019 | 5.500 |
Why?
|
| Radiography, Thoracic | 21 | 2020 | 320 | 4.300 |
Why?
|
| Lung Neoplasms | 21 | 2020 | 2014 | 3.340 |
Why?
|
| Alveolitis, Extrinsic Allergic | 5 | 2020 | 28 | 2.460 |
Why?
|
| Diagnosis, Differential | 33 | 2020 | 1575 | 2.400 |
Why?
|
| Lymph Nodes | 7 | 2019 | 523 | 2.310 |
Why?
|
| Diagnostic Imaging | 12 | 2020 | 437 | 2.200 |
Why?
|
| Humans | 175 | 2021 | 79054 | 2.130 |
Why?
|
| Connective Tissue Diseases | 5 | 2021 | 66 | 1.860 |
Why?
|
| Lung Diseases | 9 | 2020 | 260 | 1.810 |
Why?
|
| Idiopathic Interstitial Pneumonias | 9 | 2019 | 30 | 1.740 |
Why?
|
| Solitary Pulmonary Nodule | 5 | 2018 | 137 | 1.710 |
Why?
|
| Practice Guidelines as Topic | 11 | 2020 | 1067 | 1.690 |
Why?
|
| Dyspnea | 5 | 2020 | 78 | 1.670 |
Why?
|
| Incidental Findings | 5 | 2018 | 90 | 1.640 |
Why?
|
| Urinary Bladder Neoplasms | 7 | 2021 | 315 | 1.600 |
Why?
|
| Utilization Review | 2 | 2019 | 22 | 1.580 |
Why?
|
| Middle Aged | 73 | 2021 | 24806 | 1.580 |
Why?
|
| Radiology | 11 | 2019 | 169 | 1.490 |
Why?
|
| Aged | 57 | 2021 | 17876 | 1.470 |
Why?
|
| Multiple Pulmonary Nodules | 3 | 2018 | 5 | 1.460 |
Why?
|
| Thoracic Injuries | 6 | 2020 | 29 | 1.430 |
Why?
|
| Wounds, Nonpenetrating | 4 | 2020 | 64 | 1.420 |
Why?
|
| Radiology Department, Hospital | 2 | 2018 | 27 | 1.400 |
Why?
|
| Cough | 3 | 2020 | 46 | 1.380 |
Why?
|
| Male | 79 | 2021 | 40546 | 1.350 |
Why?
|
| Female | 80 | 2021 | 43039 | 1.340 |
Why?
|
| Aortic Diseases | 3 | 2019 | 104 | 1.310 |
Why?
|
| Interdisciplinary Communication | 2 | 2018 | 134 | 1.300 |
Why?
|
| Pulmonary Fibrosis | 6 | 2020 | 117 | 1.290 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 167 | 1.270 |
Why?
|
| Aorta, Thoracic | 3 | 2019 | 168 | 1.270 |
Why?
|
| Biopsy | 8 | 2021 | 1133 | 1.200 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2021 | 3133 | 1.130 |
Why?
|
| Societies, Medical | 15 | 2021 | 510 | 1.120 |
Why?
|
| Scleroderma, Systemic | 3 | 2020 | 39 | 1.120 |
Why?
|
| Reproducibility of Results | 13 | 2021 | 2593 | 1.120 |
Why?
|
| Sensitivity and Specificity | 14 | 2021 | 2059 | 1.040 |
Why?
|
| Mediastinum | 3 | 2019 | 45 | 1.040 |
Why?
|
| Coronary Artery Disease | 5 | 2019 | 331 | 1.030 |
Why?
|
| Mucin-5B | 3 | 2019 | 13 | 1.020 |
Why?
|
| Contrast Media | 14 | 2019 | 1050 | 1.000 |
Why?
|
| Retrospective Studies | 25 | 2021 | 7060 | 0.950 |
Why?
|
| Phthalazines | 2 | 2018 | 27 | 0.940 |
Why?
|
| Radiology Information Systems | 3 | 2018 | 78 | 0.930 |
Why?
|
| Pulmonary Embolism | 3 | 2020 | 186 | 0.930 |
Why?
|
| Pleura | 3 | 2020 | 30 | 0.920 |
Why?
|
| Sarcoidosis, Pulmonary | 3 | 2019 | 16 | 0.920 |
Why?
|
| Predictive Value of Tests | 6 | 2020 | 1657 | 0.910 |
Why?
|
| Pulmonary Artery | 4 | 2019 | 289 | 0.880 |
Why?
|
| BRCA2 Protein | 2 | 2018 | 130 | 0.880 |
Why?
|
| Early Detection of Cancer | 3 | 2018 | 281 | 0.880 |
Why?
|
| Genomics | 9 | 2021 | 581 | 0.860 |
Why?
|
| Survival Analysis | 5 | 2018 | 1575 | 0.850 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 501 | 0.850 |
Why?
|
| Coronary Angiography | 7 | 2019 | 219 | 0.850 |
Why?
|
| Fluorodeoxyglucose F18 | 8 | 2018 | 124 | 0.850 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2020 | 918 | 0.840 |
Why?
|
| Radiopharmaceuticals | 8 | 2018 | 167 | 0.830 |
Why?
|
| Piperazines | 2 | 2018 | 260 | 0.830 |
Why?
|
| Quality Assurance, Health Care | 2 | 2018 | 221 | 0.830 |
Why?
|
| Pleural Diseases | 2 | 2016 | 12 | 0.820 |
Why?
|
| Granuloma | 3 | 2016 | 52 | 0.810 |
Why?
|
| Positron-Emission Tomography | 6 | 2016 | 276 | 0.800 |
Why?
|
| Pulmonary Alveoli | 2 | 2016 | 84 | 0.770 |
Why?
|
| Pneumonia, Bacterial | 2 | 2016 | 27 | 0.770 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 13 | 0.760 |
Why?
|
| Carcinoma, Transitional Cell | 4 | 2020 | 141 | 0.760 |
Why?
|
| Cohort Studies | 13 | 2021 | 2569 | 0.760 |
Why?
|
| Autoimmune Diseases | 2 | 2017 | 227 | 0.750 |
Why?
|
| Urothelium | 1 | 2018 | 64 | 0.740 |
Why?
|
| Feedback | 1 | 2018 | 110 | 0.730 |
Why?
|
| Technology, Radiologic | 1 | 2018 | 101 | 0.720 |
Why?
|
| Adult | 40 | 2021 | 25041 | 0.720 |
Why?
|
| Gadolinium | 3 | 2014 | 105 | 0.700 |
Why?
|
| Physician Incentive Plans | 1 | 2016 | 20 | 0.700 |
Why?
|
| United States | 22 | 2021 | 5960 | 0.690 |
Why?
|
| Efficiency | 1 | 2016 | 37 | 0.690 |
Why?
|
| Speech Recognition Software | 1 | 2016 | 5 | 0.680 |
Why?
|
| Medical Audit | 1 | 2016 | 37 | 0.670 |
Why?
|
| Peer Review | 1 | 2016 | 18 | 0.670 |
Why?
|
| Fibrosis | 6 | 2020 | 174 | 0.670 |
Why?
|
| Tracheomalacia | 1 | 2016 | 2 | 0.670 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2016 | 6 | 0.660 |
Why?
|
| Medical Records | 1 | 2016 | 121 | 0.660 |
Why?
|
| Prognosis | 14 | 2020 | 3591 | 0.660 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2016 | 45 | 0.640 |
Why?
|
| Gases | 1 | 2015 | 28 | 0.630 |
Why?
|
| Prevalence | 7 | 2019 | 1192 | 0.630 |
Why?
|
| Breast Implants | 1 | 2015 | 31 | 0.630 |
Why?
|
| Birt-Hogg-Dube Syndrome | 2 | 2014 | 3 | 0.630 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2013 | 166 | 0.620 |
Why?
|
| Cryptogenic Organizing Pneumonia | 2 | 2012 | 6 | 0.620 |
Why?
|
| Lymphangioleiomyomatosis | 2 | 2014 | 9 | 0.620 |
Why?
|
| Calcinosis | 1 | 2016 | 237 | 0.610 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2014 | 18 | 0.610 |
Why?
|
| Tracheal Diseases | 2 | 2013 | 12 | 0.610 |
Why?
|
| Psoriasis | 4 | 2018 | 212 | 0.600 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 402 | 0.600 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 377 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2021 | 858 | 0.590 |
Why?
|
| Lung Transplantation | 2 | 2018 | 231 | 0.590 |
Why?
|
| Faculty, Medical | 1 | 2016 | 165 | 0.590 |
Why?
|
| Evidence-Based Medicine | 11 | 2020 | 432 | 0.580 |
Why?
|
| Carcinoma | 1 | 2018 | 432 | 0.580 |
Why?
|
| Motivation | 1 | 2016 | 242 | 0.580 |
Why?
|
| Lymphatic Diseases | 1 | 2014 | 38 | 0.580 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2014 | 23 | 0.570 |
Why?
|
| Cysts | 2 | 2014 | 100 | 0.570 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2019 | 116 | 0.570 |
Why?
|
| Pulmonary Valve | 2 | 2020 | 26 | 0.570 |
Why?
|
| Chronic Disease | 7 | 2020 | 938 | 0.550 |
Why?
|
| Testicular Neoplasms | 3 | 2019 | 103 | 0.550 |
Why?
|
| Observer Variation | 4 | 2020 | 620 | 0.550 |
Why?
|
| Cystectomy | 5 | 2021 | 65 | 0.540 |
Why?
|
| Sarcoidosis | 1 | 2014 | 88 | 0.530 |
Why?
|
| Pulmonary Circulation | 2 | 2012 | 81 | 0.530 |
Why?
|
| Ventricular Septum | 1 | 2012 | 12 | 0.530 |
Why?
|
| Pulmonary Subvalvular Stenosis | 1 | 2012 | 1 | 0.520 |
Why?
|
| Mass Screening | 1 | 2017 | 601 | 0.520 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 73 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2020 | 1021 | 0.500 |
Why?
|
| Image Enhancement | 2 | 2013 | 584 | 0.500 |
Why?
|
| Echocardiography | 4 | 2020 | 829 | 0.500 |
Why?
|
| Systole | 1 | 2012 | 141 | 0.500 |
Why?
|
| Aneurysm | 1 | 2012 | 56 | 0.500 |
Why?
|
| Disease Progression | 6 | 2019 | 1414 | 0.500 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2011 | 6 | 0.490 |
Why?
|
| Mutation | 7 | 2021 | 3724 | 0.490 |
Why?
|
| Myocardial Ischemia | 1 | 2013 | 162 | 0.490 |
Why?
|
| Smoking | 3 | 2017 | 560 | 0.490 |
Why?
|
| Pulmonary Infarction | 1 | 2010 | 1 | 0.470 |
Why?
|
| Immunocompromised Host | 3 | 2019 | 136 | 0.460 |
Why?
|
| Respiratory Distress Syndrome, Adult | 2 | 2015 | 93 | 0.450 |
Why?
|
| Hematoma | 1 | 2011 | 91 | 0.450 |
Why?
|
| Lung Diseases, Fungal | 1 | 2010 | 26 | 0.450 |
Why?
|
| Mucormycosis | 1 | 2010 | 15 | 0.450 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 396 | 0.440 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 286 | 0.440 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 312 | 0.440 |
Why?
|
| Mitral Valve | 1 | 2012 | 217 | 0.440 |
Why?
|
| Amyloidosis | 1 | 2010 | 75 | 0.430 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2009 | 5 | 0.420 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 2333 | 0.410 |
Why?
|
| Graft Rejection | 1 | 2016 | 1090 | 0.410 |
Why?
|
| Phenotype | 6 | 2019 | 2193 | 0.400 |
Why?
|
| Heart Diseases | 1 | 2012 | 306 | 0.400 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 6388 | 0.400 |
Why?
|
| Colorado | 3 | 2019 | 34 | 0.400 |
Why?
|
| Receptor, erbB-2 | 3 | 2020 | 189 | 0.390 |
Why?
|
| Radiographic Image Enhancement | 4 | 2016 | 467 | 0.390 |
Why?
|
| Asthma | 1 | 2016 | 810 | 0.390 |
Why?
|
| DNA, Neoplasm | 2 | 2020 | 278 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2208 | 0.380 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2019 | 37 | 0.380 |
Why?
|
| Aorta | 2 | 2020 | 283 | 0.360 |
Why?
|
| Heart Defects, Congenital | 2 | 2018 | 329 | 0.360 |
Why?
|
| Neoplasm Invasiveness | 5 | 2021 | 531 | 0.360 |
Why?
|
| Respiratory Tract Diseases | 2 | 2018 | 43 | 0.350 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2019 | 95 | 0.350 |
Why?
|
| Respiratory Tract Infections | 3 | 2019 | 98 | 0.350 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 1225 | 0.350 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 245 | 0.340 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 411 | 0.340 |
Why?
|
| Respiratory-Gated Imaging Techniques | 2 | 2016 | 4 | 0.340 |
Why?
|
| Genotype | 4 | 2017 | 1810 | 0.330 |
Why?
|
| Hematologic Neoplasms | 1 | 2009 | 282 | 0.330 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 1012 | 0.320 |
Why?
|
| DiGeorge Syndrome | 2 | 2017 | 14 | 0.320 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2017 | 144 | 0.310 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 613 | 0.310 |
Why?
|
| Algorithms | 7 | 2019 | 1806 | 0.310 |
Why?
|
| Feasibility Studies | 3 | 2020 | 714 | 0.300 |
Why?
|
| Stroke | 1 | 2012 | 745 | 0.290 |
Why?
|
| Angiography | 3 | 2014 | 202 | 0.280 |
Why?
|
| Treatment Outcome | 10 | 2020 | 7605 | 0.280 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 1906 | 0.280 |
Why?
|
| Hypertension, Pulmonary | 3 | 2018 | 324 | 0.270 |
Why?
|
| Biological Specimen Banks | 2 | 2020 | 40 | 0.270 |
Why?
|
| Carcinoma, Bronchogenic | 2 | 2013 | 30 | 0.270 |
Why?
|
| Hemoptysis | 2 | 2014 | 23 | 0.260 |
Why?
|
| Multidetector Computed Tomography | 3 | 2019 | 55 | 0.250 |
Why?
|
| Serologic Tests | 2 | 2020 | 45 | 0.250 |
Why?
|
| Software | 3 | 2018 | 628 | 0.250 |
Why?
|
| Medical History Taking | 2 | 2020 | 81 | 0.250 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2019 | 38 | 0.240 |
Why?
|
| Genetic Variation | 2 | 2019 | 1314 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 698 | 0.240 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 33 | 0.240 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 262 | 0.240 |
Why?
|
| Pandemics | 3 | 2020 | 428 | 0.230 |
Why?
|
| Atrial Septum | 2 | 2010 | 9 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 1192 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 5 | 2021 | 264 | 0.230 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2020 | 2 | 0.230 |
Why?
|
| Inhalation Exposure | 1 | 2020 | 21 | 0.230 |
Why?
|
| Gastropexy | 1 | 2020 | 1 | 0.220 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2010 | 61 | 0.220 |
Why?
|
| Ossification, Heterotopic | 1 | 2020 | 33 | 0.220 |
Why?
|
| Bronchiolitis | 3 | 2015 | 4 | 0.220 |
Why?
|
| Internship and Residency | 1 | 2009 | 865 | 0.220 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2016 | 566 | 0.220 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 126 | 0.220 |
Why?
|
| Radiation Dosage | 2 | 2019 | 219 | 0.220 |
Why?
|
| France | 1 | 2020 | 48 | 0.220 |
Why?
|
| Piperidines | 2 | 2018 | 165 | 0.220 |
Why?
|
| Brazil | 1 | 2020 | 67 | 0.210 |
Why?
|
| Genome | 2 | 2020 | 336 | 0.210 |
Why?
|
| Coronavirus | 1 | 2020 | 16 | 0.210 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 25 | 0.210 |
Why?
|
| Gastrostomy | 1 | 2020 | 77 | 0.210 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2019 | 46 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 2243 | 0.210 |
Why?
|
| Survival Rate | 3 | 2019 | 1910 | 0.210 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2019 | 12 | 0.210 |
Why?
|
| Risk Factors | 7 | 2019 | 5178 | 0.210 |
Why?
|
| Autoimmunity | 2 | 2018 | 161 | 0.210 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 115 | 0.210 |
Why?
|
| Medicare Part B | 1 | 2019 | 3 | 0.210 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 96 | 0.200 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 70 | 0.200 |
Why?
|
| Arthritis, Psoriatic | 1 | 2019 | 31 | 0.200 |
Why?
|
| Artifacts | 3 | 2019 | 234 | 0.200 |
Why?
|
| Hematopoietic System | 1 | 2018 | 14 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 18 | 0.200 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 755 | 0.200 |
Why?
|
| Referral and Consultation | 2 | 2019 | 310 | 0.200 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 48 | 0.200 |
Why?
|
| Seminoma | 1 | 2018 | 13 | 0.200 |
Why?
|
| Mediastinal Neoplasms | 1 | 2019 | 49 | 0.200 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 115 | 0.200 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 41 | 0.200 |
Why?
|
| Quinazolines | 2 | 2018 | 219 | 0.200 |
Why?
|
| Parathyroid Neoplasms | 1 | 2018 | 62 | 0.190 |
Why?
|
| Statistics as Topic | 2 | 2017 | 234 | 0.190 |
Why?
|
| Prospective Studies | 7 | 2021 | 3812 | 0.190 |
Why?
|
| Comparative Effectiveness Research | 2 | 2016 | 45 | 0.190 |
Why?
|
| Autoantibodies | 1 | 2019 | 253 | 0.190 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 1320 | 0.190 |
Why?
|
| Databases, Factual | 2 | 2020 | 787 | 0.190 |
Why?
|
| Carbazoles | 1 | 2018 | 52 | 0.190 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 63 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 545 | 0.190 |
Why?
|
| Amygdala | 1 | 2018 | 75 | 0.190 |
Why?
|
| Drug Substitution | 1 | 2018 | 26 | 0.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 466 | 0.190 |
Why?
|
| Occupational Diseases | 2 | 2016 | 54 | 0.190 |
Why?
|
| Pulmonary Emphysema | 1 | 2017 | 22 | 0.190 |
Why?
|
| Lymphocytes | 1 | 2020 | 468 | 0.190 |
Why?
|
| Vasculitis | 1 | 2017 | 39 | 0.190 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 63 | 0.190 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 27 | 0.180 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 23 | 0.180 |
Why?
|
| Transcriptome | 1 | 2021 | 435 | 0.180 |
Why?
|
| Tetralogy of Fallot | 1 | 2017 | 40 | 0.180 |
Why?
|
| Acetylcysteine | 1 | 2018 | 75 | 0.180 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 75 | 0.180 |
Why?
|
| Antirheumatic Agents | 1 | 2017 | 48 | 0.180 |
Why?
|
| Adiposity | 1 | 2017 | 76 | 0.180 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2017 | 29 | 0.180 |
Why?
|
| Risk Assessment | 4 | 2020 | 2186 | 0.180 |
Why?
|
| Coronary Vessels | 1 | 2019 | 180 | 0.180 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2016 | 18 | 0.180 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1771 | 0.180 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 36 | 0.180 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 235 | 0.180 |
Why?
|
| Registries | 2 | 2017 | 599 | 0.170 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2016 | 22 | 0.170 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2019 | 460 | 0.170 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2016 | 4 | 0.170 |
Why?
|
| Software Validation | 1 | 2016 | 4 | 0.170 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 123 | 0.170 |
Why?
|
| Myositis | 1 | 2016 | 15 | 0.170 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 131 | 0.170 |
Why?
|
| Mycobacterium avium Complex | 1 | 2016 | 9 | 0.170 |
Why?
|
| Repressor Proteins | 1 | 2019 | 387 | 0.170 |
Why?
|
| Azathioprine | 1 | 2016 | 122 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 928 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 361 | 0.160 |
Why?
|
| Atmospheric Pressure | 1 | 2015 | 4 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 160 | 0.160 |
Why?
|
| Altitude | 1 | 2015 | 40 | 0.160 |
Why?
|
| Hospitalization | 2 | 2018 | 721 | 0.160 |
Why?
|
| Neuroendocrine Cells | 1 | 2015 | 2 | 0.160 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 237 | 0.150 |
Why?
|
| Rib Fractures | 1 | 2014 | 4 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2018 | 302 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 205 | 0.150 |
Why?
|
| Pneumonia, Aspiration | 1 | 2014 | 19 | 0.150 |
Why?
|
| Cystic Fibrosis | 1 | 2016 | 127 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2016 | 218 | 0.150 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 691 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2018 | 679 | 0.150 |
Why?
|
| Heterozygote | 1 | 2016 | 365 | 0.150 |
Why?
|
| Acute Disease | 4 | 2019 | 847 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 367 | 0.150 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 147 | 0.150 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2014 | 26 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 2687 | 0.150 |
Why?
|
| Emphysema | 1 | 2014 | 14 | 0.150 |
Why?
|
| Glass | 1 | 2014 | 15 | 0.140 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2014 | 7 | 0.140 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 268 | 0.140 |
Why?
|
| Heart Ventricles | 1 | 2020 | 747 | 0.140 |
Why?
|
| Bronchoscopy | 4 | 2020 | 133 | 0.140 |
Why?
|
| Bronchial Diseases | 1 | 2013 | 12 | 0.140 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 1010 | 0.140 |
Why?
|
| User-Computer Interface | 2 | 2012 | 184 | 0.140 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 1426 | 0.140 |
Why?
|
| Thorax | 1 | 2013 | 50 | 0.140 |
Why?
|
| Protons | 1 | 2013 | 92 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2016 | 263 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 630 | 0.130 |
Why?
|
| Antibodies, Antinuclear | 3 | 2018 | 88 | 0.130 |
Why?
|
| Comorbidity | 1 | 2017 | 877 | 0.130 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 98 | 0.130 |
Why?
|
| Gene Rearrangement | 3 | 2018 | 162 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 557 | 0.130 |
Why?
|
| Phantoms, Imaging | 2 | 2014 | 390 | 0.130 |
Why?
|
| Cleft Palate | 1 | 2012 | 23 | 0.130 |
Why?
|
| Mediastinitis | 1 | 2012 | 14 | 0.130 |
Why?
|
| Histoplasmosis | 1 | 2012 | 22 | 0.130 |
Why?
|
| Pulmonary Diffusing Capacity | 3 | 2017 | 24 | 0.130 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 58 | 0.130 |
Why?
|
| Vital Capacity | 3 | 2017 | 56 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2012 | 37 | 0.130 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2012 | 21 | 0.130 |
Why?
|
| Pericarditis, Constrictive | 1 | 2012 | 5 | 0.130 |
Why?
|
| Critical Care | 1 | 2015 | 344 | 0.130 |
Why?
|
| Cardiac Tamponade | 1 | 2012 | 19 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2011 | 23 | 0.120 |
Why?
|
| Alleles | 1 | 2016 | 1086 | 0.120 |
Why?
|
| Chicago | 1 | 2017 | 1377 | 0.120 |
Why?
|
| Inflammation | 1 | 2017 | 768 | 0.120 |
Why?
|
| Atlases as Topic | 1 | 2011 | 7 | 0.120 |
Why?
|
| Thoracic Diseases | 1 | 2012 | 26 | 0.120 |
Why?
|
| Heart Septum | 1 | 2012 | 47 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 803 | 0.120 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 93 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1484 | 0.110 |
Why?
|
| Tomography, Spiral Computed | 1 | 2011 | 75 | 0.110 |
Why?
|
| Bronchiectasis | 1 | 2010 | 12 | 0.110 |
Why?
|
| Young Adult | 5 | 2021 | 5660 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 283 | 0.110 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2012 | 163 | 0.110 |
Why?
|
| Hypotension | 1 | 2010 | 70 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 228 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2011 | 217 | 0.110 |
Why?
|
| African Americans | 1 | 2018 | 1110 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2017 | 930 | 0.110 |
Why?
|
| Fever | 1 | 2010 | 122 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2012 | 248 | 0.110 |
Why?
|
| Italy | 2 | 2021 | 102 | 0.110 |
Why?
|
| Delphi Technique | 3 | 2014 | 62 | 0.110 |
Why?
|
| Bacteremia | 1 | 2010 | 112 | 0.110 |
Why?
|
| Logistic Models | 3 | 2018 | 1133 | 0.100 |
Why?
|
| Trachea | 1 | 2011 | 308 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 1386 | 0.100 |
Why?
|
| Washington | 1 | 2009 | 43 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 912 | 0.100 |
Why?
|
| Respiratory Function Tests | 2 | 2019 | 138 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3749 | 0.100 |
Why?
|
| INDEL Mutation | 2 | 2018 | 22 | 0.100 |
Why?
|
| Professional Competence | 1 | 2009 | 71 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 348 | 0.100 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1713 | 0.100 |
Why?
|
| Time Factors | 4 | 2020 | 5386 | 0.100 |
Why?
|
| HIV Infections | 1 | 2016 | 686 | 0.100 |
Why?
|
| Palliative Care | 1 | 2010 | 248 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2010 | 171 | 0.090 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2011 | 545 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 543 | 0.090 |
Why?
|
| Adolescent | 4 | 2021 | 8818 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 534 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 787 | 0.080 |
Why?
|
| Forced Expiratory Volume | 2 | 2015 | 110 | 0.080 |
Why?
|
| Patient Selection | 2 | 2020 | 674 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 759 | 0.080 |
Why?
|
| Neoplasms | 1 | 2019 | 2495 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2021 | 672 | 0.070 |
Why?
|
| Child | 3 | 2021 | 6431 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 859 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 1145 | 0.070 |
Why?
|
| ROC Curve | 2 | 2019 | 736 | 0.070 |
Why?
|
| Iopamidol | 2 | 2013 | 8 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2021 | 3705 | 0.070 |
Why?
|
| Radiography | 2 | 2016 | 864 | 0.070 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 22 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2019 | 3239 | 0.060 |
Why?
|
| New York | 1 | 2020 | 59 | 0.060 |
Why?
|
| Muscles | 1 | 2021 | 187 | 0.060 |
Why?
|
| Cryosurgery | 1 | 2020 | 41 | 0.060 |
Why?
|
| Ontario | 1 | 2020 | 53 | 0.060 |
Why?
|
| Cardiac Output | 1 | 2020 | 151 | 0.050 |
Why?
|
| North America | 1 | 2020 | 175 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2021 | 494 | 0.050 |
Why?
|
| Telomerase | 1 | 2019 | 51 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2021 | 276 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 2132 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2021 | 514 | 0.050 |
Why?
|
| Genomic Structural Variation | 1 | 2019 | 3 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 59 | 0.050 |
Why?
|
| Organ Size | 1 | 2020 | 379 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 2359 | 0.050 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 2018 | 9 | 0.050 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2018 | 4 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2018 | 7 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 298 | 0.050 |
Why?
|
| Motion | 1 | 2019 | 71 | 0.050 |
Why?
|
| Equipment Design | 1 | 2020 | 415 | 0.050 |
Why?
|
| Necrosis | 1 | 2019 | 202 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 48 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 37 | 0.050 |
Why?
|
| NIH 3T3 Cells | 1 | 2018 | 106 | 0.050 |
Why?
|
| Consensus | 1 | 2020 | 278 | 0.050 |
Why?
|
| Anilides | 1 | 2018 | 48 | 0.050 |
Why?
|
| Mutation Rate | 1 | 2018 | 43 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 464 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2020 | 687 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 143 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2017 | 87 | 0.050 |
Why?
|
| Propensity Score | 1 | 2018 | 131 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2018 | 303 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 482 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2019 | 175 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 238 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 281 | 0.050 |
Why?
|
| Phototherapy | 1 | 2017 | 34 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2018 | 164 | 0.050 |
Why?
|
| Rheumatoid Factor | 1 | 2017 | 18 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2018 | 233 | 0.050 |
Why?
|
| Whole Body Imaging | 1 | 2017 | 38 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 105 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2018 | 218 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 173 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 267 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2017 | 306 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 153 | 0.040 |
Why?
|
| Pneumocystis carinii | 1 | 2016 | 2 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 450 | 0.040 |
Why?
|
| Hypersplenism | 1 | 2016 | 2 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1576 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 205 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2018 | 778 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 182 | 0.040 |
Why?
|
| Pyridines | 1 | 2018 | 294 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 689 | 0.040 |
Why?
|
| Leukopenia | 1 | 2016 | 65 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 84 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 360 | 0.040 |
Why?
|
| Arthritis | 1 | 2016 | 42 | 0.040 |
Why?
|
| Silicosis | 1 | 2016 | 1 | 0.040 |
Why?
|
| Anthracosis | 1 | 2016 | 1 | 0.040 |
Why?
|
| Asbestosis | 1 | 2016 | 5 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 967 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2016 | 53 | 0.040 |
Why?
|
| Heart Rate | 1 | 2019 | 515 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2016 | 106 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 361 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2017 | 231 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2020 | 599 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2017 | 475 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 378 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 336 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2020 | 449 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2016 | 359 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 399 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2334 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1206 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2016 | 173 | 0.040 |
Why?
|
| Animals | 2 | 2018 | 26207 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2019 | 1086 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 270 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 324 | 0.040 |
Why?
|
| Physical Examination | 1 | 2016 | 150 | 0.040 |
Why?
|
| Lung Abscess | 1 | 2014 | 7 | 0.040 |
Why?
|
| Chromatin | 1 | 2017 | 320 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2015 | 151 | 0.040 |
Why?
|
| Multiple Trauma | 1 | 2014 | 30 | 0.040 |
Why?
|
| Thoracic Wall | 1 | 2014 | 20 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 703 | 0.040 |
Why?
|
| Infant | 1 | 2021 | 3031 | 0.040 |
Why?
|
| Pleural Effusion | 1 | 2014 | 47 | 0.040 |
Why?
|
| Diaphragm | 1 | 2014 | 53 | 0.040 |
Why?
|
| Aortography | 1 | 2014 | 63 | 0.040 |
Why?
|
| Lung Injury | 1 | 2014 | 46 | 0.040 |
Why?
|
| Chest Pain | 1 | 2014 | 40 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 94 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 102 | 0.040 |
Why?
|
| Foreign Bodies | 1 | 2014 | 63 | 0.040 |
Why?
|
| Tracheal Neoplasms | 1 | 2013 | 7 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1334 | 0.040 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2013 | 13 | 0.040 |
Why?
|
| Evidence-Based Dentistry | 1 | 2013 | 9 | 0.030 |
Why?
|
| Bronchial Neoplasms | 1 | 2013 | 9 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 2080 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 867 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 551 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2016 | 869 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2014 | 115 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 681 | 0.030 |
Why?
|
| Gene Order | 1 | 2012 | 25 | 0.030 |
Why?
|
| Health Policy | 1 | 2014 | 162 | 0.030 |
Why?
|
| Inpatients | 1 | 2015 | 248 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 433 | 0.030 |
Why?
|
| Collagen Diseases | 1 | 2012 | 3 | 0.030 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2012 | 3 | 0.030 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 24 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 389 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 1193 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1805 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2015 | 345 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 2152 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 209 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2013 | 192 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2012 | 60 | 0.030 |
Why?
|
| Diastole | 1 | 2012 | 145 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2011 | 339 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 668 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2012 | 211 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2014 | 1022 | 0.030 |
Why?
|
| Cell Survival | 1 | 2011 | 1008 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 2410 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2010 | 551 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 10772 | 0.020 |
Why?
|